U.S. markets close in 1 hour 54 minutes

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
113.69-0.96 (-0.83%)
As of 2:05PM EST. Market open.
Sign in to post a message.
  • S
    Simon
    JPMORGAN analyst has CRSP at Markoutperform with PT at $160. Goodluck and go CRSP!
    Bullish
  • V
    VirginiaLova
    CRISPR Therapeutics on TV Today — CBS Sunday Morning at 9:00 AM EST.

    SCIENCE: CRISPR and "The Code Breaker"
    Visionary biochemist Jennifer Doudna shared the Nobel Prize last year for the gene-editing technique known as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), which has the potential to cure diseases caused by genetic mutations. Correspondent David Pogue talks with Doudna about the promises and perils of this technology; and with Walter Isaacson, author of the new book "The Code Breaker," about why the biotech revolution will dwarf the digital revolution in importance.

    BOOK EXCERPT: Walter Isaacson's "The Code Breaker"

    For more info:

    "The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race" by Walter Isaacson (Simon & Schuster), in Hardcover, eBook and Audio formats, available via Amazon and Indiebound
    Walter Isaacson, Tulane University
    Doudna Lab, Berkeley, Calif.
    Innovative Genomics Institute, Berkeley, Calif.
    CRISPR Therapeutics, Cambridge, Mass.
    Sarah Cannon, Nashville, Tenn.

    $NTLA
    Bullish
  • V
    VirginiaLova
    Crispr was on CNBC this morning. The author of Code Breaker called Crispr bigger than the digital revolution. He only writes books on the best of the best in the world. Other books he wrote cover Einstein, for example.
    Bullish
  • R
    Rob
    JMP Securities is not the only financial services company getting on board the CRISPR train in recent days. On Monday, Barclays analyst Gena Wang dramatically increased her price target on the stock to $140 per share from the previous $113, while keeping an overweight (again, buy) recommendation. Wang was particularly impressed by the company's progress in several of its clinical programs, as indicated in its fourth-quarter earnings release published last month.
    Other companies remain optimistic about CRISPR's prospects. In the wake of those earnings, Oppenheimer raised its price target by 13% to $187 per share; almost needless to say, it has the equivalent of a buy recommendation on the stock. Goldman Sachs actually lowered its price target slightly (to $189 from $193) and maintained its neutral rating, but the bank's latest level is now 63% above the current share price.
  • J
    John
    Major Institution announced 10 million share purchase in crisper
  • V
    VirginiaLova
    The bulls on the CRSP Cas9 system are coming out of the woodwork. Lentiviral vectors will never be approved and the FDA clearly wanted CRSP over Blue (based on the technology).
    Bullish
  • C
    Charles
    Looking at the recent drop from another perspective: this stock has dropped almost 100 its from the high, but on March 9th, 2020 it was 37.64 and today it is 114.65...have the long term view...the science is proven and we have great results...I am happy even if it drops more...good news coming...hang tough.
    Bullish
  • V
    VirginiaLova
    $CRSP — CRISPR Therapeutics to Participate in Upcoming Investor Conferences
    ZUG, Switzerland and CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:

    Barclays Global Healthcare Conference
    Date: Tuesday, March 9, 2021
    Time: 10:20 a.m. ET

    33rd Annual Roth Conference
    Date: Monday, March 15, 2021
    Time: 1:30 p.m. ET
    Bullish
  • W
    Wasabi
    Just a reminder that everyone is starting to look at CRISPR for their Portfolio- following is the article from Motley Fool:
    CRISPR Therapeutics is at the forefront of treating various types of cancer and hereditary blood disorders via immuno- and gene therapy. Each year, about 360,000 babies worldwide are born with either sickle cell disease (SCD) or beta thalassemia. In the case of the former, the disease distorts the shape of patients' hemoglobin. This, in turn, can cause a life-threatening condition called a vaso-occlusive crisis (VOC), in which irregular-shaped red blood cells clump up and constrict blood vessels. Beta thalassemia can significantly reduce a patients' level of hemoglobin. Patients who suffer from either condition require frequent blood transfusions and hospitalization. There is no cure for the two disorders aside from a bone marrow transplant.
    But CRISPR Therapeutics might be coming to the rescue. In phase 1/2 clinical trials, patients who received its CTX001 gene therapy transfusion saw their hemoglobin levels return to normal, were free of VOCs, and no longer depended on transfusions. Additionally, the company's CTX110 immunotherapy managed to eliminate tumor activity completely in 4 out of 11 patients with lymphoma. The patients all had advanced-stage cancer and went through two to five different therapies before enrolling in CTX110 trials.
    At the moment, pharma companies that make drugs to treat SCD are valued at upwards of $3 billion, while biotechs that successfully advance immunotherapies to market could see up to $21 billion in valuation. Given CRISPR Therapeutics' $9.9 billion market cap, the stock still has quite a bit to go before it might be considered overvalued. The company also has more than $1.69 billion in cash with just $348.9 million per year in losses. Given the strength of its science and its financial health, this is one biotech that's sure to add wealth to your portfolio.
  • V
    VirginiaLova
    CRISPR Therapeutics to Participate in Upcoming Investor Conferences
    ZUG, Switzerland and CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:

    Barclays Global Healthcare Conference
    Date: Tuesday, March 9, 2021
    Time: 10:20 a.m. ET

    33rd Annual Roth Conference
    Date: Monday, March 15, 2021
    Time: 1:30 p.m. ET

    A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.
    Bullish
  • T
    Travis
    Do people that follow CRSP do the math and think CRSP will someday be worth 1 Trillion dollar company? I would like to know your thoughts by the numbers. If this tech is used to cure so many different things....what does the value look like in 10 years? ideas please. thanks in advance. Just doing some reasearch.
    Bullish
  • R
    Rob
    It’s funny how everyone is thinking that the company they have invested in has problems and it dropped, on each company board here on Yahoo Finance, when in reality it is a whole market situation because of the bond yields. It has nothing to do with any particular company, be it this one or any other.

    I see CRSP being in the same situation as before, having tremendous potential and waiting for important research and testing results this year. The price action has nothing to do with the company’s fundamentals.
    Bullish
  • L
    Lilly from Istanbul 🐰
    $BNGO conversation
    I believe short term investors both pushed BNGO far beyond where they should be today. At $2 BNGO was an incredibly good investment. At $15, not. Same company. Same product. It doesn't mean it's a bad company.It means that the company is worth less than $15/share right now. It needs to grow more before it's worth $15/share. It will be worth $15/share some day. It will be worth $50/share some day. But, not today. Today, it's worth $5. When i first bought BNGO at $1 I had absolutely no clue a bunch of people would push the stock price to $15/share. That price is not based on any type of logic, fundamentals, or future projections. It's based on a bunch of rookies who don't know how to think.

    $BNGO $PACB $SENS $NDRA $CRSP
    Neutral
  • V
    VirginiaLova
    Bulls on CRSP are coming out in force. Cas9 is it. This is bigger than the internet. It is bigger than EV.
    Bullish
  • Z
    ZIM
    Crispr Therapeutics: Paving The Way For The Genomic Revolution, But Perhaps Too Early To Go All-In
    Mar. 01, 2021 9:34 AM ET | by BK Tan

    (from article, SeekingAlpha)

    Summary

    We have come a long way from medicine of the past, and technology will serve to accelerate the adoption of genomics as mainstream medicine.
    CRSP, led by the original founders of the CRISPR/Cas9 gene-editing technology, has significant potential in their pipeline.
    A bottom-up, risk-adjusted DCF for each of its pipeline components reveals that it is roughly at fair value based on the price at the time of writing.
    Because of the probabilistic nature of its pipeline at this stage, I believe it is prudent to continue observing for more positive indications in its clinical trials that can increase the expected value of the treatments, before considering a large stake in the firm.

    Introduction

    The paradigm of healthcare has shifted tremendously over the centuries. Indeed, we have come a long way from the prescription of spiritual cures to where we are now with medical technology and advanced chemical synthesis of pharmaceutical products seeking to target even the vilest of illnesses. But much more lies in store for the future of medicine. Previously thought to be impossible due to the large-scale computing power required, scientists sequenced the first human genome in 2003. And with the discovery of the CRISPR/Cas9 gene editing techniques, a new paradigm of medicine has emerged – the genomic revolution which seeks to revolutionize treatments to target the very fundamental unit of life itself. Pioneering this technology are 2020 Chemistry Nobel Prize winners Jennifer Doudna and Emmanuelle Charpentier who stand at the helm of Crispr Therapeutics (CRSP). Understandably, there is much reason to believe in the expertise of these scientists to guide the future of cures in the genomic therapeutic space.
    Bullish
  • I
    Ira
    Parabolic coming!!!!
    Bullish
  • D
    Deav
    CBS Sunday morning Code Breakers piece. very high profile show and well done. Our Noble prize winner interviewed and the promise continues. I believe we're almost finished our "round trip" with the stock and should be returning to ATH's in the sort term.
  • C
    Charlie
    Looking into the crystal ball I have on my desk, I would think large cap value (and other value) stocks to top out mid to late summer. The growth stocks and sectors will start awakening again. Growth stocks are slightly down YTD - small cap the most - after significant rises last year and early this year. There is nothing that is going to hold back innovative and disruptive growth companies though. The future is bright. Particularly for the best of the best, and CRSP, I believe is one of those.
    Bullish
  • r
    robert
    This is a critical test for CRSP. Right now it is resting squarely on the 200 day moving average having well breached the 50 and 100 day averages. We are nearing capitulation right now. Hopefully the 200 day holds. Even it if it doesn't CRSP isn't going down forever. But this for sure is a test. It is extremely oversold on the relative strength index. Common sense should kick in soon and the market should quit taking the genomics names, which have a very solid future, through the wood chipper. Hang on for a little longer longs blue skies are ahead.
    Bullish